Cerecin Expands Leadership Team with Appointment of Chief Medical Officer and Chief Operating Officer

Cerecin Bolsters Pipeline with a Strategic Acquisition From Boston Scientific

Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders

Cerecin strengthens position in neurometabolism with addition to pipeline

Cerecin to Present New Infantile Spasms Data at the 35th Interna1onal Epilepsy Congress, Dublin 2023

Clinical Trial Data of Novel Metabolic Mechanism in Migraine: CER-0001, a Ketogenic Investigational Agent